13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001600004
Total reported value
$1.6B
$1.6B
38 檔
17.4%
During the Q2 2025 filing period, First Light Asset Management, LLC (CIK: 0001600004) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.6B across 38 reported positions.
First Light Asset Management, LLC executed strategic sector rebalancing during Q2 2025, establishing 8 new positions while fully exiting 7 holdings and trimming 19 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ANAB | Anaptysbio Inc | Stock-Other | 10.19% | -0.42% | -23.61% | |
| 2 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 7.31% | -5.56% | EXIT | |
| 3 | PFMTUSD | Performant Financial CORP | Stock-Other | 6.83% | — | +12.63% | |
| 4 | NEO | Neogenomics Inc | Stock-Healthcare | 6.49% | +4.42% | +13.30% | |
| 5 | AXGN | Axogen Inc | Stock-Other | 6.37% | -4.16% | +1.23% | |
| 6 | HCAT | Health Catalyst Inc | Stock-Other | 5.98% | +0.08% | +17.18% | |
| 7 | TWST | Twist Bioscience CORP | Stock-Other | 4.51% | +0.81% | -22.46% | |
| 8 | ATRC | Atricure Inc | Stock-Other | 4.31% | -0.90% | -22.78% | |
| 9 | SIBN | Si-bone Inc | Stock-Other | 4.27% | +2.00% | +8.60% | |
| 10 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 3.74% | -0.57% | -42.36% | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.22% | -0.45% | +1.02% | |
| 12 | ORGO | Organogenesis Holdings Inc | Stock-Other | 3.22% | -0.74% | EXIT | |
| 13 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.91% | -0.13% | -7.46% | |
| 14 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.58% | — | -13.31% | |
| 15 | ✓ | Establishment Labs Holdings In | Stock-Other | 2.31% | -0.28% | +23.83% | |
| 16 | ADMA | Adma Biologics Inc | Stock-Healthcare | 2.25% | — | — | |
| 17 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 2.21% | — | +666.68% | |
| 18 | KRMD | Koru Medical Systems Inc | Stock-Other | 2.17% | -0.60% | +5.09% | |
| 19 | NPCE | Neuropace Inc | Stock-Other | 1.99% | -0.14% | -12.86% | |
| 20 | VERA | Vera Therapeutics Inc | Stock-Other | 1.72% | -1.13% | EXIT | |
| 21 | MDXG | Mimedx Group Inc | Stock-Other | 1.53% | -1.01% | EXIT | |
| 22 | CAI | Caris Life Sciences Inc | Stock-Other | 1.46% | — | — | |
| 23 | BFLY | Butterfly Network Inc | Stock-Other | 1.42% | +0.39% | -0.74% | |
| 24 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 25 | EVH | Evolent Health Inc - A | Stock-Other | 1.08% | — | +26.15% | |
| 26 | MASS | 908 Devices Inc | Stock-Other | 0.99% | -0.01% | -37.24% | |
| 27 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.91% | — | +11.67% | |
| 28 | GH | Guardant Health Inc | Stock-Healthcare | 0.87% | +1.71% | -52.47% | |
| 29 | INSM | Insmed Inc | Stock-Healthcare | 0.82% | — | -7.71% | |
| 30 | SLP | Simulations Plus Inc | Stock-Other | 0.81% | +0.32% | — | |
| 31 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.76% | — | -70.00% | |
| 32 | RGEN | Repligen CORP | Stock-Healthcare | 0.71% | — | -49.97% | |
| 33 | ALHC | Alignment Healthcare Inc | Stock-Other | 0.70% | — | -59.89% | |
| 34 | EOLS | Evolus Inc | Stock-Other | 0.62% | — | — | |
| 35 | RDNT | Radnet Inc | Stock-Healthcare | 0.51% | — | — | |
| 36 | JANX | Janux Therapeutics Inc | Stock-Other | 0.45% | — | -77.29% | |
| 37 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.33% | — | -7.67% | |
| 38 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.32% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ORGO | Organogenesis Holdings Inc | +3.2% | NEW | New buy |
| 2 | PFMTUSD | Performant Financial CORP | +2.9% | +12.63% | Add |
| 3 | ADMA | Adma Biologics Inc | +2.3% | NEW | New buy |
| 4 | SENS1GBP | Senseonics Holdings Inc | +1.9% | +666.68% | Add |
| 5 | SIBN | Si-bone Inc | +1.7% | +8.60% | Add |
| 6 | CAI | Caris Life Sciences Inc | +1.5% | NEW | New buy |
| 7 | CDTX | Cidara Therapeutics Inc | +1.1% | NEW | New buy |
| 8 | KRMD | Koru Medical Systems Inc | +0.9% | +5.09% | Add |
| 9 | SLP | Simulations Plus Inc | +0.8% | NEW | New buy |
| 10 | ✓ | Establishment Labs Holdings In | +0.7% | +23.83% | Add |
| 11 | EOLS | Evolus Inc | +0.6% | NEW | New buy |
| 12 | HCAT | Health Catalyst Inc | +0.6% | +17.18% | Add |
| 13 | RDNT | Radnet Inc | +0.5% | NEW | New buy |
| 14 | EVH | Evolent Health Inc - A | +0.5% | +26.15% | Add |
| 15 | ANAB | Anaptysbio Inc | +0.4% | -23.61% | Trim |
| 16 | LNTH | Lantheus Holdings Inc | +0.3% | NEW | New buy |
| 17 | INSM | Insmed Inc | +0.2% | -7.71% | Trim |
| 18 | MASS | 908 Devices Inc | +0.1% | -37.24% | Trim |
| 19 | GPCR | Structure Therapeutics Inc | +0.1% | -7.67% | Trim |
| 20 | ELDN | Eledon Pharmaceuticals Inc | 0% | +11.67% | Add |
| 21 | BFLY | Butterfly Network Inc | 0% | -0.74% | Trim |
| 22 | RARE | Ultragenyx Pharmaceutical In | 0% | -13.31% | Trim |
| 23 | NEO | Neogenomics Inc | -0.1% | +13.30% | Add |
| 24 | CRNX | Crinetics Pharmaceuticals In | -0.1% | +1.02% | Add |
| 25 | IRTC | Irhythm Holdings Inc | -0.2% | -42.36% | Trim |
| 26 | NPCE | Neuropace Inc | -0.2% | -12.86% | Trim |
| 27 | LABDGBP | Drx Dly S&p Biotech Bear 3x | -0.3% | EXIT | Sold out |
| 28 | PCVX | Vaxcyte Inc | -0.4% | EXIT | Sold out |
| 29 | GH | Guardant Health Inc | -0.5% | -52.47% | Trim |
| 30 | PODD | Insulet CORP | -0.5% | EXIT | Sold out |
| 31 | ATRC | Atricure Inc | -0.5% | -22.78% | Trim |
| 32 | TNDM | Tandem Diabetes Care Inc | -0.5% | EXIT | Sold out |
| 33 | RGEN | Repligen CORP | -0.6% | -49.97% | Trim |
| 34 | 260 | Centessa Pharmaceuticals-adr | -0.7% | -11.91% | Trim |
| 35 | FNAUSD | Paragon 28 Inc | -0.8% | EXIT | Sold out |
| 36 | OSCR | Oscar Health Inc - Class A | -0.8% | EXIT | Sold out |
| 37 | TMDX | Transmedics Group Inc | -0.8% | EXIT | Sold out |
| 38 | TWST | Twist Bioscience CORP | -1% | -22.46% | Trim |
| 39 | ALHC | Alignment Healthcare Inc | -1.3% | -59.89% | Trim |
| 40 | MDXG | Mimedx Group Inc | -1.5% | -44.18% | Trim |
| 41 | VERA | Vera Therapeutics Inc | -1.5% | -52.12% | Trim |
| 42 | JANX | Janux Therapeutics Inc | -1.6% | -77.29% | Trim |
| 43 | XENE | Xenon Pharmaceuticals Inc | -1.7% | -70.00% | Trim |
| 44 | EWTX | Edgewise Therapeutics Inc | -1.7% | -7.46% | Trim |
| 45 | AXGN | Axogen Inc | -3.1% | +1.23% | Add |
According to official SEC Form 13F filings, First Light Asset Management, LLC reported a total U.S. public equity portfolio value of $1.6B across 38 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ANAB, 260, PFMTUSD) accounted for 17.4% of total reported equity market value during Q2 2025.
Top New Position Initiated
ORGO
市值: $24.8M
Top Position Liquidated / Trimmed
TMDX
前期市值: $7.3M
During Q2 2025, First Light Asset Management, LLC's top holdings by market value included ANAB (10.2%)、260 (7.3%)、PFMTUSD (6.8%). The largest single position, ANAB, represented 10.2% of total portfolio value.
In Q2 2025, First Light Asset Management, LLC made 45 total portfolio adjustments, initiating 8 new buys, adding to 11 positions, trimming 19 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.